ArticleBiochemistry and biophysics reports2026
Identification of PI3K/AKT/mTOR-related genes as diagnostic biomarkers for cutaneous squamous cell carcinoma.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of cancer-associated fibroblast biomarkers in cutaneous squamous cell carcinoma.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer. Considering the substantial improvement in prognosis when detected at an early stage, identifying biomarkers for an early diagnosis of cSCC is crucial. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway plays a crucial role in cSCC progression; This study aimed to identify PI3K/AKT/mTOR-related genes that may serve as diagnostic indicators for cSCC, thereby providing a diagnostic framework for this disease. Methods/results: A total of 33 PI3K/AKT/mTOR-related differentially expressed genes (DEGs) in cSCC were acquired by intersecting the DEGs from the Gene Expression Omnibus database between normal and cSCC groups and genes reported to be associated with the PI3K/AKT/mTOR pathway in the literature. LASSO regression identified 11 hub genes ( Conclusion: These five PI3K/AKT/mTOR-related genes have the potential to serve as clinical biomarkers for the diagnosis of cSCC and as candidate therapeutic targets. This study offers valuable insights for further research to elucidate the specific pathological mechanisms and establish innovative treatment approaches for cSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.